Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
Michael Mauer, Alexey Sokolovskiy, Jay A. Barth, Jeffrey P. Castelli, Hadis N. Williams, Elfrida R. Benjamin, Behzad Najafian
Dive into the research topics of 'Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment'. Together they form a unique fingerprint.